MLMartin B. Leon

Martin B. Leon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin B. Leon has a total of 333 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Associations of Mild or Trace Valvular Abnormalities With Cardiac Remodeling in Older Adults: The ARIC Study

    by Yumin Gao, Jonathan Rubin, Susan Cheng, Lena Mathews, Ajay J. Kirtane, Ron C. Hoogeveen, Christie M. Ballantyne, Elizabeth Selvin, Martin B. Leon, Josef Coresh, et al.

    Background: The impact of mild/trace valvular abnormalities on cardiac remodeling is not well understood, despite their association with poor cardiovascular outcomes. Methods: Using data from 4684 participants in the ARIC (Atherosclerosis Risk in Communities) Study (2011–2013), aged 66 to 90 years, we examined cross‐sectional associations of mild/trace valvular abnormalities (aortic stenosis, aortic regurgitation, and mitral regurgitation) with cardiac parameters using multivariable linear regression models. Cardiac parameters included cardiac structure (eg, left ventricular mass index), systolic function (eg, ejection fraction), diastolic function, and biomarkers (eg, high‐sensitivity cardiac troponin T). Results: The prevalence was 4.3% for mild aortic stenosis, 10.9% for mild/trace aortic regurgitation, and 44.7% for mild/trace mitral regurgitation. Mitral regurgitation showed the most consistent associations with cardiac measures (left ventricular mass index 5.48 g/m 2 [95% CI, 4.38–6.57 g/m 2 ]; ejection fraction –1.92% [95% CI, −2.29% to −1.54%]; high‐sensitivity cardiac troponin T 0.08 log ng/L [95% CI, 0.05–0.12 log ng/L]). Aortic stenosis was associated with impaired ventricular filling (Ratio of early transmitral flow velocity to early diastolic mitral annular velocity (E/e’) lateral ratio 2.00 [95% CI, 1.48–2.53]) and elevated biomarkers (high‐sensitivity cardiac troponin T 0.17 ng/L [95% CI, 0.09–0.25 ng/L]), whereas aortic regurgitation was associated with worsened cardiac structure (left ventricular mass index 3.52 [95% CI, 1.76–5.28] g/m 2 ) and systolic dysfunction (ejection fraction −1.54% [95% CI, −2.14% to −0.94%]). A dose–response relationship was also observed between the number of total abnormalities and all cardiac parameters examined. Conclusions: Mild/trace mitral regurgitation was most consistently associated with all cardiac parameters examined. Aortic stenosis was associated with elevated E/e’ lateral ratio and high‐sensitivity cardiac troponin T, whereas aortic regurgitation was associated with worsening in cardiac structure and ejection fraction. Our study supports the possibility of pathophysiological contributions of these mild/trace valvular abnormalities.

  • Impact of Initial Valve Type on Reintervention for TAVR Failure: From the EXPLANTORREDO-TAVR International Registry

    by Syed Zaid, Tsuyoshi Kaneko, Ole De Backer, Sachin S. Goel, Paolo Denti, Thomas Modine, Tamim N. Nazif, Martin B. Leon, Michael J. Mack, Vinayak N. Bapat, et al.

    BACKGROUND: As transcatheter aortic valve replacement (TAVR) expands to younger patients, there is limited data on the impact of TAV type on outcomes of TAVR-explant and redo-TAVR for TAVR failure. We sought to compare outcomes of reintervention for failed balloon-expandable valves (BEV) versus self-expanding valves (SEV). METHODS: From May 2009 to February 2022, 553 patients from 29 centers in the international EXPLANTORREDO-TAVR registry underwent redo-TAVR or TAVR-explant for TAVR failure during a separate admission from index TAVR. Mechanically expanding valves and explantation for endocarditis were excluded. 158 (41.4%) failed-BEV were compared with 224 (58.6%) failed-SEV, and outcomes were reported at 30 days and 1 year. RESULTS: Mean age at reintervention was 75.5±9.3 years, and 40.6% were female. Failed-BEV had higher proportion of structural valve deterioration (73.4% versus 46.1% in failed-SEV; P P =0.022) and fewer paravalvular leak (18.2% versus 41.1%; P P P =0.92), with cross-platform redo-TAVR favored in both groups (58.1% of failed-BEV received SEV; 59.2% of failed-SEV received BEV; P =0.016). Compared with failed-SEV, reintervention for failed-BEV had similar mortality at 30 days (8.7% versus 8.0%; P =0.85) and 1 year (24.3% versus 21.5%; P =0.65), with no differences in risk-adjusted 3-year cumulative mortality when stratified by reintervention type (redo TAVR: adjusted hazard ratio, 1.15 [0.61–2.20]; ref: failed-BEV); TAVR-explant: adjusted hazard ratio, 0.84 [0.46–1.54]). CONCLUSIONS: Failed-BEV and failed-SEV showed distinct failure mechanisms and timing of reintervention, but initial valve type did not impact reintervention strategy or survival after redo-TAVR or TAVR-explant.


  • Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry

    by Brian R. Lindman, Linda D. Gillam, Elizabeth M. Perpetua, Sammy Elmariah, Catherine M. Otto, Marielle Scherrer-Crosbie, Patrick T. O’GAra, Martin B. Leon, Michael Mack, Vinod Thourani, et al.

    BACKGROUND: Undertreatment and delayed treatment of aortic stenosis (AS) are common, both of which are associated with increased mortality. Historically, assessment of quality for AS care has focused on peri- and postprocedural outcomes. The American Heart Association Target: AS registry is the first national registry to provide data and evaluate quality for upstream processes of care for patients with AS. METHODS: Randomly selected patients from 2023 and 2024 with moderate or severe AS from 58 sites in the Target: AS registry were included. The 2 primary quality measures were (1) timely diagnosis (percentage of patients with an echocardiogram consistent with possible severe AS who had all assessments to clarify AS severity and symptoms within 30 days) and (2) timely treatment (percentage of patients with a Class I indication for aortic valve replacement treated within 90 days). Secondary measures included documentation of key echocardiographic parameters in the report, clinical recommendations in the echocardiogram report summary, multidisciplinary heart valve team evaluation, guideline-based performance of multimodality testing, and timely surveillance echocardiograms. RESULTS: Among 8097 patients, 47% were women, 7% Black, 6% Hispanic, and 3% Asian. Timely diagnosis occurred in 54% in 2023, improving to 61% in 2024 ( P =0.027) with gaps caused by lack of timely symptom assessment (23% [2023]; 16% [2024]), lack of stroke volume index (35% [2023]; 18% [2024]), or lack of timely multimodality testing (87% [2023]; 75% [2024]). Among those with a Class I indication for aortic valve replacement, timely treatment occurred in 82% (2023) versus 85% (2024) ( P =NS). Multidisciplinary heart valve team evaluation occurred in 78% (2023) versus 84% (2024) ( P =0.008). Key findings in the echocardiography report were documented in 83% (2023) and 85% (2024) ( P =NS), but a clinical recommendation was included in <10% of the time. Timely surveillance echocardiograms for moderate (2 years) and severe AS (1 year) were not performed in ~40% of patients. CONCLUSIONS: The national American Heart Association Target: AS registry demonstrates opportunities for improvement in timely diagnosis, surveillance, and treatment for patients with AS at participating centers. By providing an infrastructure to measure performance and identify best practices, the Target: AS registry has the potential to elevate and optimize care and patient outcomes.


  • Open Access

    Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial

    by Kashish Goel, Brian R. Lindman, Allan Schwartz, David J. Cohen, Gennaro Giustino, J. Bradley Oldemeyer, Justin Strote, Vasilis Babaliaros, Chandan M. Devireddy, Michael P. Fischbein, et al.

    BACKGROUND: The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus a CS strategy by age is unknown. METHODS: The study population of the EARLY TAVR trial was stratified into 4 age groups: 65 to 69 years (n=141), 70 to 74 years (n=263), 75 to 79 years (n=250), and ≥80 years (n=247). Associations between age and the trial primary end point of death, stroke, or unplanned cardiovascular hospitalization; the composite end point of death, stroke, or heart failure hospitalization; and its individual components were examined. Interaction tests evaluated whether the treatment effect of early TAVR versus CS differed by age. RESULTS: No interaction was detected between age and the treatment effect of early TAVR versus CS for the composite or individual outcomes. We observed lower stroke rates with early TAVR compared with CS in the youngest (65–69 years, absolute risk reduction, 13%; P =0.008) and oldest (≥80 years; absolute risk reduction, 12.3%; P =0.029) age groups. The absolute difference in heart failure hospitalization rates between the early TAVR and CS arms at 2 years was greatest in the oldest patients (≥80 years, 9.1%; 75–79 years, 5.9%; 70–74 years, 5.1%; 65–69 years, 4.4%). In the CS group, time to conversion to AVR was similar across all age groups (median, 11 months; P =0.73). Approximately one-third of younger patients (65–69 years) in the CS arm presented with acute valve syndrome at the time of conversion, and the frequency tended to increase with age ( P =0.06). CONCLUSIONS: In the EARLY TAVR trial, the relative benefit of early TAVR over CS was consistent among all age groups. The greatest absolute reduction in stroke rate with early TAVR compared with CS appeared in the youngest and oldest groups, whereas reduction in heart failure hospitalization was most pronounced in the oldest patients. These data suggest that early TAVR should be considered in all age groups above 65 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03042104.


  • Open Access

    Early Postrranscatheter Aortic Valve Replacement Heart Failure Hospitalization and Outcomes in Older Patients

    by Harun Kundi, Martin Leon, David J. Cohen, Alexandra Popma, Yukari Kobayashi, Bjorn Redfors, Lauren S. Ranard, Maria C. Alu, Julia B. Thompson, Jennifer von Stein, et al.

    Background: Transcatheter aortic valve replacement (TAVR) improves symptoms and survival in patients with severe aortic stenosis, yet the incidence and prognostic significance of early postprocedural heart failure (HF) hospitalization remain incompletely characterized. Our objective is to determine the incidence, clinical characteristics, prognostic implications, and predictors of early HF hospitalization after TAVR. Methods: Using the Medicare Provider Analysis and Review database, we identified fee‐for‐service beneficiaries ≥65 years who underwent TAVR between January 1, 2017, and November 30, 2021. Early post‐TAVR HF hospitalization was defined as at least 1 HF readmission occurring between 31 and 365 days after the index procedure. Patients were classified according to the presence or absence of HF hospitalization during this period. Cox proportional hazards models were used to evaluate the association with mortality after adjustment for clinical, procedural, and sociodemographic factors. Results: Among 233 309 patients undergoing TAVR, 45 502 (19.5%) experienced HF hospitalization within 1 year. Patients with early HF hospitalization had markedly higher mortality compared with those without HF hospitalization, including 1‐year mortality (43.8% versus 3.6%) and 5‐year mortality (80.6% versus 41.0%) (log‐rank P <0.001). After multivariable adjustment, early HF hospitalization was strongly associated with increased mortality (adjusted hazard ratio [HR], 3.17 [95% CI, 3.11–3.22]). The strongest predictors of early HF hospitalization were advanced cardiac damage stage (adjusted‐subdistribution HR, 1.95 [95% CI, 1.88–2.02]) and high‐risk frailty (adjusted‐subdistribution HR, 1.65 [95% CI, 1.58–1.72]), with graded risk across stages. Conclusions: Nearly 1 in 5 older adults undergoing TAVR experience early HF hospitalization, which is associated with markedly increased short‐ and long‐term mortality.

  • Impact of TAVR Failure Mechanism on Outcomes After Reintervention: From the EXPLANTORREDO-TAVR Registry

    by Bhavanadhar Penta, Gilbert H.L. Tang, Mohamed Abdel-Wahab, Rik Adrichem, Hasan Ahmad, Martin Andreas, Anita W. Asgar, Igor Belluschi, Walid Ben-Ali, Oliver D. Bhadra, et al.

    BACKGROUND: As transcatheter aortic valve replacement (TAVR) expands to patients with longer life expectancy, the impact of failure mechanisms on outcomes of TAVR-explant and redo-TAVR remains uncertain. We sought to evaluate outcomes of TAVR reintervention based on the failure mechanism of the index transcatheter aortic valve. METHODS: From 2009 to 2022, 553 patients from 29 centers in the EXPLANTORREDO-TAVR registry (Explant or Redo Transcatheter Aortic Valve Replacement) underwent TAVR-explant or redo-TAVR for transcatheter aortic valve failure. Patients with endocarditis were excluded. Patients with structural valve deterioration (SVD, N=224 [64.9%]) were compared with those with nonstructural valve dysfunction (NSVD, N=121 [35.1%]), comprising paravalvular leak (86.0%) and prosthesis-patient mismatch (14.0%). Outcomes were assessed at 30 days and 1 year. RESULTS: Mean age was 75.6±9.3 years, with 42% women. There were no differences in reintervention type between groups (redo-TAVR in 58.0% SVD versus 49.6% NSVD; TAVR-explant: 42.0% versus 50.4%; P =0.14). Compared with NSVD, SVD was the predominant mode of failure in balloon-expandable valves (50.7% versus 24.8%; P P P =0.003). Mortality at 30 days and 1 year did not differ significantly between SVD and NSVD for either redo-TAVR (30 days: 3.2% versus 1.7%, P =1.00; 1 year: 18.0% versus 12.0%; P =0.47) or TAVR-explant (30 days: 16.3% versus 12.1%, P =0.63; 1 year: 40.0% versus 29.5%; P =0.39). There were also no differences in risk-adjusted 3-year cumulative mortality between groups (redo-TAVR: hazard ratio, 1.30 [95% CI, 0.68–2.46], P =0.43 [ref=NSVD]; TAVR-explant: hazard ratio, 1.24 [95% CI, 0.64–2.41]; P =0.53). CONCLUSIONS: SVD and NSVD failures had distinct valve types and reintervention timing, with SVD having a longer time to TAVR reintervention, but the failure mechanism did not impact reintervention type or clinical outcomes.


  • Impact of Proportionality of Secondary Tricuspid Regurgitation on Outcomes After Tricuspid Transcatheter Edge-to-Edge Repair

    by Giulio Russo, Daniela Pedicino, Marianna Adamo, Hannes Alessandrini, Martin Andreas, Daniel Braun, Kim A. Connelly, Paolo Denti, Rodrigo Estevez-Loureiro, Neil Fam, et al.

    BACKGROUND: The impact of proportionality to heart valve regurgitation has been widely investigated in mitral regurgitation, helping to better characterize the best candidates for therapies. However, it has never been studied in tricuspid regurgitation (TR). The aim of the present study is to investigate the impact of the proportionality of TR on outcomes. METHODS: Patients undergoing tricuspid transcatheter edge-to-edge repair were selected from the TRIVALVE registry (International Multisite Transcatheter Tricuspid Valve Therapies Registry). Patients were divided according to the ratio between effective regurgitant orifice area (EROA) and right ventricular (RV) end diastolic diameter (RVEDD) into tertiles: patients with low EROA/RVEDD (RV, dominant); intermediate EROA/RVEDD (RV and TR, RV-TR, codominant), and high EROA/RVEDD (TR, dominant). The primary outcome was all-cause mortality. Median follow-up was 9.7 months (4.2–12.0). RESULTS: A total of 204 patients were included in the present study: 67 for the RV dominant, 68 for the RV-TR codominant, and 69 for the TR dominant group. The 3 groups presented different baseline characteristics. Survival analysis among the 3 groups showed a trend towards worse prognosis for the RV-dominant group, as compared with the RV-TR codominant and TR dominant groups. CONCLUSIONS: The conceptual framework of proportionality is applicable to TR with EROA/RVEDD, defining a higher risk RV-dominant phenotype with a trend towards worse survival after tricuspid transcatheter edge-to-edge repair.


  • Angiography-Derived Fractional Flow Reserve During Percutaneous Coronary Intervention

    by Chieh Yang Christopher Koo, Siling Li, Rasha Al-Lamee, David J. Cohen, William F. Fearon, Ajay J. Kirtane, Martin B. Leon, Guy Witberg, Robert W. Yeh, Eric A. Secemsky

    BACKGROUND: Angiography-derived fractional flow reserve (Angio-FFR) is an emerging tool for guiding percutaneous coronary intervention (PCI). Its uptake and outcomes compared with pressure wire (PW)-based assessment in the United States are unknown. METHODS: We conducted a cohort study using US Medicare beneficiary data from January 1, 2019 to December 31, 2024. Propensity score matching (1:3) of Angio-FFR to PW was performed in patients who underwent PCI during the same procedure, and separately among those who did not undergo PCI during the same procedure. The primary outcome was the cumulative incidence of major adverse cardiovascular events through 2 years, including all-cause death, myocardial infarction, and repeat revascularization. Secondary outcomes included individual major adverse cardiovascular event components, 30-day acute kidney injury, and 30-day major bleeding. Falsification end points (hospitalization for pneumonia and hip fracture) were used to assess unmeasured confounding. RESULTS: Of 466 535 angiograms that included intraprocedural physiological assessment, 1.00% (N=4672) used Angio-FFR. Annual use increased from 0.47% in 2019 to 3.85% in 2024. Among patients with PCI, 1591 Angio-FFR and 4773 PW-matched patients with PCI had similar major adverse cardiovascular event rates through 2 years (24.8% versus 23.5%; hazard ratio, 1.01 [95% CI, 0.85–1.20]). Secondary outcomes and falsification end points were not significantly different. In non-PCI patients, 2532 Angio-FFR and 7596 PW-matched patients also had similar major adverse cardiovascular events through 2 years (24.1% versus 23.9%; hazard ratio, 0.97 [95% CI, 0.84–1.11]). CONCLUSIONS: Angio-FFR usage in the United States is modest but increasing. Angio-FFR guidance during angiography versus PW was associated with comparable outcomes through 2 years.


  • Open Access

    Sex‐Related Differences in the Management and Outcomes of Patients Across the Spectrum of Aortic Stenosis

    by Augustin Coisne, David Montaigne, Andrea Scotti, Samy Aghezzaf, Marjorie Richardson, Sandro Ninni, Gilles Lemesle, Arnaud Sudre, Laura Butruille, Thomas Modine, et al.

    Background: There are conflicting data on sex differences in patients with aortic stenosis (AS). We aimed to investigate sex differences in management and outcomes across the spectrum of outpatients with AS. Methods: Between 2016 and 2017, consecutive all‐comer outpatients with mild (peak aortic velocity=2.5–2.9 m/s), moderate (3–3.9 m/s), or severe (≥4 m/s) native AS were included by 117 cardiologists and followed up for 5 years for aortic valve replacement (AVR) and cause of death. Outcomes were compared by sex using inverse probability of treatment weighting adjustment. Results: Among the 2704 patients, 1257 (46.5%) were women. Women were more symptomatic (New York Heart Association class ≥2, 67.7% versus 54.6%; P P =0.02) at inclusion. During follow‐up (median, 5.0 [interquartile range, 3.4–5.5]) years, 993 AVRs (488 surgical and 505 transcatheter) and 1098 deaths occurred. After inverse probability of treatment weight adjustment, women had better survival (adjusted hazard ratio [HR], 0.81 [95% CI, 0.71–0.93]; P =0.003) but similar cardiovascular death ( P =0.99) compared with men. Interestingly, the higher survival in women was observed only in mild AS (adjusted HR, 0.71 [95% CI, 0.56–0.90]; P =0.005). The inverse probability of treatment weight–adjusted cumulative incidence of AVR by AS severity revealed no significant differences between women and men among patients across the AS spectrum. Cumulative incidence of surgical AVR was lower in women than in men ( P =0.02). Conclusions: Women had a similar referral rate for AVR (versus men), with a lower proportion undergoing SAVR, allowing similar outcomes between women and men with moderate and severe AS. The lower mortality rate in women was restricted to mild AS presentation.


  • Outcomes of Patients With New Left Bundle Branch Block After TAVR: TVT Registry Insights

    by Nickpreet Singh, David J. Cohen, Shmuel Chen, Miloni A. Shah, Amanda Stebbins, Andrzej S. Kosinski, Leo Brothers, Sreekanth Vemulapalli, Ajay J. Kirtane, Jose M. Dizon, et al.

    BACKGROUND: Cardiac conduction disturbances remain the most frequent complication of transcatheter aortic valve replacement (TAVR), but the clinical implications of new left bundle branch block (LBBB) after TAVR remain controversial. Here, we aim to assess the impact of new LBBB after TAVR on patient outcomes in a large, real-world registry. METHODS: The study population consisted of patients in the TVT registry (Society of Thoracic Surgery and American College of Cardiology Transcatheter Valve Therapy Registry) who underwent TAVR for aortic stenosis between 2016 and 2022 and were discharged alive from the index hospitalization. Key exclusion criteria included preexisting conduction defects and a permanent pacemaker before TAVR or during the index hospitalization. Clinical outcomes were compared between patients with and without new LBBB using Cox proportional hazards models adjusted for baseline demographic, clinical, and echocardiographic variables. RESULTS: Among 202 533 TAVR recipients, 32 933 (16.3%) developed new LBBB after TAVR. Over the study period, there was a significant decrease in the incidence of new LBBB from 19.9% in the first quarter of 2016 to 14.4% in the third quarter of 2022. Patients with new LBBB after TAVR, compared with those without LBBB, had significantly greater 1-year all-cause mortality (adjusted hazard ratio, 1.19 [95% CI, 1.13–1.25]; P P P P P <0.001). CONCLUSIONS: New LBBB after TAVR is associated with worse 1-year outcomes, including death, rehospitalization, and permanent pacemaker, as well as worse health status and lower left ventricular ejection fraction. These findings suggest that continued efforts to limit the development of conduction disturbance after TAVR are warranted.